99 related articles for article (PubMed ID: 31663127)
1. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines.
Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
[TBL] [Abstract][Full Text] [Related]
2. A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR
Taghizadegan N; Firoozrai M; Nassiri M; Ariannejad H
J Cell Physiol; 2021 Jun; 236(6):4303-4312. PubMed ID: 33421131
[TBL] [Abstract][Full Text] [Related]
3. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
4. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
Riccio G; D'Avino C; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
[TBL] [Abstract][Full Text] [Related]
5. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
Shariaty Vaziri Z; Shafiee F; Akbari V
Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
[TBL] [Abstract][Full Text] [Related]
6. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
[TBL] [Abstract][Full Text] [Related]
7. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
[TBL] [Abstract][Full Text] [Related]
8. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
[TBL] [Abstract][Full Text] [Related]
9. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
[TBL] [Abstract][Full Text] [Related]
10. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
[TBL] [Abstract][Full Text] [Related]
11. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
12. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
[TBL] [Abstract][Full Text] [Related]
13. Engineering Human Pancreatic RNase 1 as an Immunotherapeutic Agent for Cancer Therapy Through Computational and Experimental Studies.
Nassiri M; Ghovvati S; Gharouni M; Tahmoorespur M; Bahrami AR; Dehghani H
Protein J; 2024 Apr; 43(2):316-332. PubMed ID: 38145445
[TBL] [Abstract][Full Text] [Related]
14. Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology.
Guerrero-Ochoa P; Aguilar-Machado D; Ibáñez-Pérez R; Macías-León J; Hurtado-Guerrero R; Raso J; Anel A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32859066
[TBL] [Abstract][Full Text] [Related]
15. Cloning, expression and characterization of a HER2-alpha luffin fusion protein in
Barkhordari F; Sohrabi N; Davami F; Mahboudi F; Garoosi YT
Prep Biochem Biotechnol; 2019; 49(8):759-766. PubMed ID: 31032734
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin.
Jinno H; Ueda M; Ozawa S; Kikuchi K; Ikeda T; Enomoto K; Kitajima M
Cancer Chemother Pharmacol; 1996; 38(4):303-8. PubMed ID: 8674151
[TBL] [Abstract][Full Text] [Related]
17. Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells.
Banisadr A; Safdari Y; Kianmehr A; Pourafshar M
Hum Vaccin Immunother; 2018 Apr; 14(4):856-863. PubMed ID: 29185855
[TBL] [Abstract][Full Text] [Related]
18. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
19. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861.
Gilabert-Oriol R; Weng A; Trautner A; Weise C; Schmid D; Bhargava C; Niesler N; Wookey PJ; Fuchs H; Thakur M
Biochem Pharmacol; 2015 Oct; 97(3):247-55. PubMed ID: 26253687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
